Jeffrey L. Quillen

Partner - Boston

Bio photo for Jeffrey Quillen
Download Media Photo

Contact Information

617.832.1205

617.832.7000

jquillen@foleyhoag.com Download vCard

Jeffrey Quillen’s varied business law practice focuses on companies involved with advanced technology applications. He serves as outside general counsel to a number of emerging biotechnology, software and information technology companies. For these and other clients he negotiates and drafts agreements regarding intellectual property rights, including patent license agreements with major research universities and collaboration agreements with pharmaceutical companies.

More »

Education:

  • Duke University School of Law, J.D., 1991
  • Colgate University, B.A., 1988

Representative Experience

  • Represented BigVisible Solutions, Inc. in the sale by its shareholders of the business to SolutionsIQ for an undisclosable amount.
  • Represented Pervasis Therapeutics in connection with a sale of substantially all of Pervasis’ assets to a subsidiary of Shire plc.
  • Represented Zosano Pharma Corporation (NASDAQ: ZSAN) in its initial public offering of 4,500,000 shares of its common stock at a price of $11.00 per share.
  • Represented Rinovum Women’s Health, a privately-held, U.S.-based women’s health company, in its Series C funding.
  • Represented Selecta Biosciences, Inc., a biopharmaceutical company founded by Dr. Omid Farokhzad and Professors Robert Langer and Ulrich von Andrian, in various equity financings totaling over $50 million, including most recently a $10 million extension of Series D financing.
  • Represented NeoGraft Technologies, a development-stage medical device company focused on coronary artery disease, in its $11 million Series C financing.
  • Advised scPharmaceuticals, Inc., a biopharmaceutical company developing transformative pharmaceutical products for subcutaneous delivery, in its $16 million Series A venture financing.
  • Represented ArthroMeda, Inc., a developer of medical devices designed to improve surgical outcomes for patients undergoing joint replacement procedures, in its Series B financing.
  • Advised Blend Therapeutics, Inc., a biopharmaceutical company discovering new classes of drugs to treat cancer and other diseases, on numerous financings, including a $16 million Series B financing.

Licensing & Strategic Alliances

  • Advised Zosano Pharma Corporation (NASDAQ: ZSAN), a California-based, biotechnology company that is a pioneer in the transdermal drug delivery field, in the negotiation of an agreement with Novo Nordisk A/S to develop a new transdermal presentation of semaglutide.
  • Advised Zosano Pharma Corporation (NASDAQ: ZSAN) in its exclusive licensing agreement with Eli Lilly and Company to develop ZP-PTH -- Zosano’s proprietary formulation of parathyroid hormone 1-34 (PTH) -- using Zosano’s microneedle patch system for the treatment of osteoporosis patients.
  • Represented Translational Therapeutics Inc. as it entered into a strategic licensing agreement with Clavis Pharma ASA of Norway regarding the development and commercialization of a thyroid cancer treatment.

Foley Hoag Alerts & Updates

Honors

  • Chambers USA, Recognized Practitioner for Private Equity: Venture Capital Investment (2018, 2019) 
  • Listed in Best Lawyers in America® - Venture Capital Law (2007-2019 Editions)
  • Listed in Best Lawyers in Massachusetts® - Venture Capital Law (2012-2017 Editions)
  • Listed in Boston's Best Lawyers® - Venture Capital Law (2008 & 2011 Editions)
  • Endorsed by PLCWhich Lawyer? for Venture Capital and Life Sciences: Commercial and Partnering (2007-2012 Editions)
  • Listed in The Legal 500 US Volume 1 (Corporate & Finance) (2006)
  • Listed in Super Lawyers - Massachusetts Rising Stars 2005 - Securities, Corporate Finance & IP

Involvement

  • Boston Bar Association, Member
  • Judge, MassChallenge Venture Funds Competition
  • Judge, Harvard Business School New Venture Competition
  • Peer Reviewer for the Massachusetts Life Sciences Center Accelerator Loan Program
  • Moderator, “Alternative Financing and Venture Philanthropy,” BioPharm America 2017, September 26, 2017 
  • Moderator, “C-Suite:  Life in Public,” BioPharm America 2016, September 13, 2016
  • Moderator, “Creating a Clinical-Stage Startup by In-licensing Assets,” BioPharm America 2015, September 15, 2015
  • Speaker, "A Quick Spin Through Spin-Offs," NYSE Life Sciences Industry Peer Exchange, April 8, 2015
  • Moderator, “Large Series A Financings Deconstructed,” BioPharm America 2014, September 22, 2014
  • Moderator, “From Discovery to Early Stage Drug Development: At the Intersection of Academia, Biotech and Pharm,” BioPharma America 2013, September 17, 2013
  • Panelist, “Creating Value with Limited Liability Companies and Asset-Centric Investing,” BIO International Convention, April 24, 2013
  • Moderator, “New Financing Models for Creative Exit Strategies,” BioPharm America 2012, September 19, 2012
  • Panelist, JOBS Act Webinar, BIO, September 18, 2012
  • Moderator, "Building a Better Biotech," Mass High Tech Annual BioForum, February 17, 2011  
  • Speaker, "Founder Follies," Harvard Business School, February 10, 2011
  • Moderator, "Nanomedicine: Next Generation of Blockbusters," BIO International Convention, May 3-5, 2010, Chicago, IL
  • Moderator, "High Risks, High Rewards: Avoiding the Pitfalls of Partnerships," Mass High Tech Annual BioForum, February 26, 2010
  • Panelist, "Picking Winners and Losers in Health Care," Emerging Enterprise Center at Foley Hoag LLP, October 22, 2009
  • Speaker, "2009 Financing Outlook," Emerging Enterprise Center at Foley Hoag LLP, September 21, 2009
  • Speaker, "Key Issues in University/Hospital Spinouts of Life Sciences Companies," MCLE Cutting-Edge Life Sciences Law and Practice Seminar, March 9, 2009
  • Moderator, "Outlook on Biotech: Survival Strategies," Mass High Tech's 7th Annual BioForum, February 5, 2009
  • American Conference Institute's Managing Legal Risks In Pharmaceutical Manufacturing Outsourcing Conference, "Incorporating Audit Rights into the Contract to Ensure Maintenance of Quality, Performance and Protection of IP," November 18, 2008
  • Panelist, "Build, Buy or Ally," New England Chapter of the Association of Strategic Alliance Professionals, September 17, 2008
  • Chair, "Virtues and Vices of Virtual Biotechnology Companies,"  BIO 2008 International Convention, June 19, 2008
  • Panelist, "Clinical Trials: Managing the Risk, Managing Expectations," William Gallagher Associates Conference, November 28, 2007
  • Moderator, "The Coming Wave…Nanobiotechnology," Massachusetts Biotechnology Council, Annual Investors Conference, November 8, 2007
  • Panelist, MIT Enterprise Forum of Cambridge Start-up Clinic, October 3, 2007
  • Moderator, "Get Smart: Successful Strategies for Negotiating with Research Institutions," BIO International Convention, May 8, 2007
  • Speaker, "Structuring the Milestone-Based Life Sciences Acquisition: Tails, Taxes and Control," American Conference Institute's Life Sciences Conference, March 14-15, 2007
Add to Bio Folder

Download Bio

Bar Admissions

  • District of Columbia
  • Massachusetts
  • Florida